Special Report on Cyclopharm (ASX:CYC): FDA approval is last piece of the puzzle

Marc Kennis Marc Kennis, March 1, 2022


Cyclopharm’s (ASX:CYC) core radiopharmaceutical product, Technegas, is used in functional lung ventilation imaging, particularly for the diagnosis of pulmonary embolism (PE). CYC is already selling in 60 countries around the world, but US FDA approval would open up the vast US market.


CYC is on of Marc & Stuart’s Top Picks. You can read the full report below!




Stay up-to-date on ASX-listed Life Sciences stocks!

Make sure you subscribe to Stocks Down Under today




No credit card needed and the trial expires automatically.

Recent Posts

metal exchanges

Should I invest in metal exchanges rather than in resources stocks?

If investing in resources stocks (particularly junior explorers) is too risky, another option is investing in metal exchanges. But is…

Leo Lithium

Leo Lithium (ASX:LLL): Here’s why it was the best ASX lithium stock and why it isn’t anymore

Investors have been excited about Leo Lithium (ASX:LLL) over the past year and so have we! We thought this was…

top investing mistakes

Here are the 5 Top investing mistakes and how to avoid them

We recap the 5 top investing mistakes that investors make. These mistakes are not the only ones investors make, but…